MALT lymphomas: pathogenesis can drive treatment
Marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent B-cell non-Hodgkin lymphoma arising from the lymphoid tissue at extranodal sites. It is genetically characterized by different, usually mutually exclusive, genetic abnormalities that lead to activation of the...
Gespeichert in:
| Veröffentlicht in: | Oncology (Williston Park, N.Y.) N.Y.), 2011-11, Vol.25 (12), p.1134-1147 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1147 |
|---|---|
| container_issue | 12 |
| container_start_page | 1134 |
| container_title | Oncology (Williston Park, N.Y.) |
| container_volume | 25 |
| creator | Bertoni, Francesco Coiffier, Bertrand Salles, Gilles Stathis, Anastasios Traverse-Glehen, Alexandra Thieblemont, Catherine Zucca, Emanuele |
| description | Marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent B-cell non-Hodgkin lymphoma arising from the lymphoid tissue at extranodal sites. It is genetically characterized by different, usually mutually exclusive, genetic abnormalities that lead to activation of the nuclear factor kappa B (NF-kappaB) pathway. These lymphomas can arise in any extranodal organ or tissue; however, the stomach--where MALT lymphoma development has been strongly linked to chronic Helicobacter pylori infection--is the most common site. Other microorganisms have been associated with non-gastric MALT lymphomas, but the evidence for such associations is weaker. Treatment aimed at eradicating H pylori infection results in remission of gastric MALT lymphoma in most patients and represents a model of anticancer treatment based on the eradication of the causative factor. Treatment of non-gastric MALT lymphomas is much less well established; either radiotherapy or systemic therapy (with chemotherapy and/or rituximab [Rituxan]) can be effective, while antibiotic therapies (e.g., doxycycline in ocular adnexal lymphomas) should still be considered investigational. |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_915385380</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A306598716</galeid><sourcerecordid>A306598716</sourcerecordid><originalsourceid>FETCH-LOGICAL-g406t-cd52288bb3c9dad8548b4945918abc54565301c40c096bad8ca6f69be2f5ee003</originalsourceid><addsrcrecordid>eNpt0V9LwzAQAPA-KG5Ov4IUBX2qXNMmJr6N4T-Y-DKfS5pe1460qUkq7NvbsglOlgQOwu-Ou-QkmAIXEAkQ8SQ4d24DQBgDfhZMyLAEgXQawPt8uQr1tukq00j3GHbSV2aNLbrahUq2YWHrbwy9RekbbP1FcFpK7fByH2fB5_PTavEaLT9e3hbzZbROgflIFZQQzvM8UaKQBacpz1ORUhFzmSuaUkYTiFUKCgTLB6AkK5nIkZQUESCZBXe7up01Xz06nzW1U6i1bNH0LhMxTfhwRnn9T25Mb9uhuUwAIwIIsAHd7NBaaszqtjTeSjWWzOYJMCr4Qzyq6IgaX8NKbVos6-H6wN8f8cMusKnV0YTbPwkVSu0rZ3Tva9O6Q3i1H6rPGyyyztaNtNvs9-eSH1oajus</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>906290206</pqid></control><display><type>article</type><title>MALT lymphomas: pathogenesis can drive treatment</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Bertoni, Francesco ; Coiffier, Bertrand ; Salles, Gilles ; Stathis, Anastasios ; Traverse-Glehen, Alexandra ; Thieblemont, Catherine ; Zucca, Emanuele</creator><creatorcontrib>Bertoni, Francesco ; Coiffier, Bertrand ; Salles, Gilles ; Stathis, Anastasios ; Traverse-Glehen, Alexandra ; Thieblemont, Catherine ; Zucca, Emanuele</creatorcontrib><description>Marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent B-cell non-Hodgkin lymphoma arising from the lymphoid tissue at extranodal sites. It is genetically characterized by different, usually mutually exclusive, genetic abnormalities that lead to activation of the nuclear factor kappa B (NF-kappaB) pathway. These lymphomas can arise in any extranodal organ or tissue; however, the stomach--where MALT lymphoma development has been strongly linked to chronic Helicobacter pylori infection--is the most common site. Other microorganisms have been associated with non-gastric MALT lymphomas, but the evidence for such associations is weaker. Treatment aimed at eradicating H pylori infection results in remission of gastric MALT lymphoma in most patients and represents a model of anticancer treatment based on the eradication of the causative factor. Treatment of non-gastric MALT lymphomas is much less well established; either radiotherapy or systemic therapy (with chemotherapy and/or rituximab [Rituxan]) can be effective, while antibiotic therapies (e.g., doxycycline in ocular adnexal lymphomas) should still be considered investigational.</description><identifier>ISSN: 0890-9091</identifier><identifier>PMID: 22229204</identifier><language>eng</language><publisher>United States: Intellisphere, LLC</publisher><subject>Anti-Bacterial Agents - therapeutic use ; Cancer ; Care and treatment ; Chromosome Aberrations ; Diagnosis ; Gene mutations ; Genetic aspects ; Health aspects ; Helicobacter Infections - complications ; Helicobacter Infections - drug therapy ; Helicobacter pylori ; Humans ; Lymphoma, B-Cell, Marginal Zone - diagnosis ; Lymphoma, B-Cell, Marginal Zone - etiology ; Lymphoma, B-Cell, Marginal Zone - pathology ; Lymphoma, B-Cell, Marginal Zone - therapy ; Lymphomas ; Physiological aspects ; Radiotherapy ; Stomach Neoplasms - etiology ; Stomach Neoplasms - therapy ; Survival Rate</subject><ispartof>Oncology (Williston Park, N.Y.), 2011-11, Vol.25 (12), p.1134-1147</ispartof><rights>COPYRIGHT 2011 Intellisphere, LLC</rights><rights>Copyright United Business Media LLC Nov 15, 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22229204$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bertoni, Francesco</creatorcontrib><creatorcontrib>Coiffier, Bertrand</creatorcontrib><creatorcontrib>Salles, Gilles</creatorcontrib><creatorcontrib>Stathis, Anastasios</creatorcontrib><creatorcontrib>Traverse-Glehen, Alexandra</creatorcontrib><creatorcontrib>Thieblemont, Catherine</creatorcontrib><creatorcontrib>Zucca, Emanuele</creatorcontrib><title>MALT lymphomas: pathogenesis can drive treatment</title><title>Oncology (Williston Park, N.Y.)</title><addtitle>Oncology (Williston Park)</addtitle><description>Marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent B-cell non-Hodgkin lymphoma arising from the lymphoid tissue at extranodal sites. It is genetically characterized by different, usually mutually exclusive, genetic abnormalities that lead to activation of the nuclear factor kappa B (NF-kappaB) pathway. These lymphomas can arise in any extranodal organ or tissue; however, the stomach--where MALT lymphoma development has been strongly linked to chronic Helicobacter pylori infection--is the most common site. Other microorganisms have been associated with non-gastric MALT lymphomas, but the evidence for such associations is weaker. Treatment aimed at eradicating H pylori infection results in remission of gastric MALT lymphoma in most patients and represents a model of anticancer treatment based on the eradication of the causative factor. Treatment of non-gastric MALT lymphomas is much less well established; either radiotherapy or systemic therapy (with chemotherapy and/or rituximab [Rituxan]) can be effective, while antibiotic therapies (e.g., doxycycline in ocular adnexal lymphomas) should still be considered investigational.</description><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Chromosome Aberrations</subject><subject>Diagnosis</subject><subject>Gene mutations</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Helicobacter Infections - complications</subject><subject>Helicobacter Infections - drug therapy</subject><subject>Helicobacter pylori</subject><subject>Humans</subject><subject>Lymphoma, B-Cell, Marginal Zone - diagnosis</subject><subject>Lymphoma, B-Cell, Marginal Zone - etiology</subject><subject>Lymphoma, B-Cell, Marginal Zone - pathology</subject><subject>Lymphoma, B-Cell, Marginal Zone - therapy</subject><subject>Lymphomas</subject><subject>Physiological aspects</subject><subject>Radiotherapy</subject><subject>Stomach Neoplasms - etiology</subject><subject>Stomach Neoplasms - therapy</subject><subject>Survival Rate</subject><issn>0890-9091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpt0V9LwzAQAPA-KG5Ov4IUBX2qXNMmJr6N4T-Y-DKfS5pe1460qUkq7NvbsglOlgQOwu-Ou-QkmAIXEAkQ8SQ4d24DQBgDfhZMyLAEgXQawPt8uQr1tukq00j3GHbSV2aNLbrahUq2YWHrbwy9RekbbP1FcFpK7fByH2fB5_PTavEaLT9e3hbzZbROgflIFZQQzvM8UaKQBacpz1ORUhFzmSuaUkYTiFUKCgTLB6AkK5nIkZQUESCZBXe7up01Xz06nzW1U6i1bNH0LhMxTfhwRnn9T25Mb9uhuUwAIwIIsAHd7NBaaszqtjTeSjWWzOYJMCr4Qzyq6IgaX8NKbVos6-H6wN8f8cMusKnV0YTbPwkVSu0rZ3Tva9O6Q3i1H6rPGyyyztaNtNvs9-eSH1oajus</recordid><startdate>20111115</startdate><enddate>20111115</enddate><creator>Bertoni, Francesco</creator><creator>Coiffier, Bertrand</creator><creator>Salles, Gilles</creator><creator>Stathis, Anastasios</creator><creator>Traverse-Glehen, Alexandra</creator><creator>Thieblemont, Catherine</creator><creator>Zucca, Emanuele</creator><general>Intellisphere, LLC</general><general>MultiMedia Healthcare Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20111115</creationdate><title>MALT lymphomas: pathogenesis can drive treatment</title><author>Bertoni, Francesco ; Coiffier, Bertrand ; Salles, Gilles ; Stathis, Anastasios ; Traverse-Glehen, Alexandra ; Thieblemont, Catherine ; Zucca, Emanuele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g406t-cd52288bb3c9dad8548b4945918abc54565301c40c096bad8ca6f69be2f5ee003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Chromosome Aberrations</topic><topic>Diagnosis</topic><topic>Gene mutations</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Helicobacter Infections - complications</topic><topic>Helicobacter Infections - drug therapy</topic><topic>Helicobacter pylori</topic><topic>Humans</topic><topic>Lymphoma, B-Cell, Marginal Zone - diagnosis</topic><topic>Lymphoma, B-Cell, Marginal Zone - etiology</topic><topic>Lymphoma, B-Cell, Marginal Zone - pathology</topic><topic>Lymphoma, B-Cell, Marginal Zone - therapy</topic><topic>Lymphomas</topic><topic>Physiological aspects</topic><topic>Radiotherapy</topic><topic>Stomach Neoplasms - etiology</topic><topic>Stomach Neoplasms - therapy</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bertoni, Francesco</creatorcontrib><creatorcontrib>Coiffier, Bertrand</creatorcontrib><creatorcontrib>Salles, Gilles</creatorcontrib><creatorcontrib>Stathis, Anastasios</creatorcontrib><creatorcontrib>Traverse-Glehen, Alexandra</creatorcontrib><creatorcontrib>Thieblemont, Catherine</creatorcontrib><creatorcontrib>Zucca, Emanuele</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology (Williston Park, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bertoni, Francesco</au><au>Coiffier, Bertrand</au><au>Salles, Gilles</au><au>Stathis, Anastasios</au><au>Traverse-Glehen, Alexandra</au><au>Thieblemont, Catherine</au><au>Zucca, Emanuele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MALT lymphomas: pathogenesis can drive treatment</atitle><jtitle>Oncology (Williston Park, N.Y.)</jtitle><addtitle>Oncology (Williston Park)</addtitle><date>2011-11-15</date><risdate>2011</risdate><volume>25</volume><issue>12</issue><spage>1134</spage><epage>1147</epage><pages>1134-1147</pages><issn>0890-9091</issn><abstract>Marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent B-cell non-Hodgkin lymphoma arising from the lymphoid tissue at extranodal sites. It is genetically characterized by different, usually mutually exclusive, genetic abnormalities that lead to activation of the nuclear factor kappa B (NF-kappaB) pathway. These lymphomas can arise in any extranodal organ or tissue; however, the stomach--where MALT lymphoma development has been strongly linked to chronic Helicobacter pylori infection--is the most common site. Other microorganisms have been associated with non-gastric MALT lymphomas, but the evidence for such associations is weaker. Treatment aimed at eradicating H pylori infection results in remission of gastric MALT lymphoma in most patients and represents a model of anticancer treatment based on the eradication of the causative factor. Treatment of non-gastric MALT lymphomas is much less well established; either radiotherapy or systemic therapy (with chemotherapy and/or rituximab [Rituxan]) can be effective, while antibiotic therapies (e.g., doxycycline in ocular adnexal lymphomas) should still be considered investigational.</abstract><cop>United States</cop><pub>Intellisphere, LLC</pub><pmid>22229204</pmid><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0890-9091 |
| ispartof | Oncology (Williston Park, N.Y.), 2011-11, Vol.25 (12), p.1134-1147 |
| issn | 0890-9091 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_915385380 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Anti-Bacterial Agents - therapeutic use Cancer Care and treatment Chromosome Aberrations Diagnosis Gene mutations Genetic aspects Health aspects Helicobacter Infections - complications Helicobacter Infections - drug therapy Helicobacter pylori Humans Lymphoma, B-Cell, Marginal Zone - diagnosis Lymphoma, B-Cell, Marginal Zone - etiology Lymphoma, B-Cell, Marginal Zone - pathology Lymphoma, B-Cell, Marginal Zone - therapy Lymphomas Physiological aspects Radiotherapy Stomach Neoplasms - etiology Stomach Neoplasms - therapy Survival Rate |
| title | MALT lymphomas: pathogenesis can drive treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T05%3A08%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MALT%20lymphomas:%20pathogenesis%20can%20drive%20treatment&rft.jtitle=Oncology%20(Williston%20Park,%20N.Y.)&rft.au=Bertoni,%20Francesco&rft.date=2011-11-15&rft.volume=25&rft.issue=12&rft.spage=1134&rft.epage=1147&rft.pages=1134-1147&rft.issn=0890-9091&rft_id=info:doi/&rft_dat=%3Cgale_proqu%3EA306598716%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=906290206&rft_id=info:pmid/22229204&rft_galeid=A306598716&rfr_iscdi=true |